LISI GROUP - Integrated report 2021

LISI – 2021 INTEGRATED REPORT — 77 Interview with Lionel Rivet Deputy CEO, LISI MEDICAL What was the market environment like in 2021? The constraints that weighed on the healthcare markets have gradually been lifted, particularly in the United States where vaccination campaigns started earlier than in Europe. The activity of the operating theaters has also normalized, which has benefited the markets in which we operate. However, hospitals are still faced with capacity challenges, particularly human capacity, which is slowing down recovery. Although the level of activity is close to that of the pre-crisis period, there has not really been any rebound effect following the catch-up of procedures that had been postponed due to COVID. However, demand has remained strong and the division, which is gaining market share in new products, ends 2021 with sales up 4.9% to €122 million. What challenges are you facing? Today’s market is focused on issues related to health expenditure, which all major developed countries are trying to control. The United States, which represents two-thirds of the world market, is at the heart of this movement, which is reflected in the strong development of private ASCs (Ambulatory Surgical Centers). The deployment of this new approach, which uses minimally invasive surgery techniques, whether or not assisted by robots, makes it possible to avoid post- operative complications and to limit lengths of hospital stays. This is at the origin of the strong development of the Minimal Invasive Surgery (MIS) markets, for which we manufacture instruments such as forceps, scissors, blades, and laparoscopic rods. Surgery is also robotized for the placement of joint or spinal reconstruction implants. These trends, fueled by demand from prime contractors who are all investing in these As hospitals gradually return to normality, the division has been able to support the recovery of demand by gainingmarket share inminimally invasive surgery instruments and consolidating its positions in the orthopedic implant segment.”